research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
Search
for
Sort by
Research
720-750 / 1000+ results research Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
research Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus
Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.
research LB943 Tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome
Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
research LB1007 Systemic treatment with a KLK5 inhibitor shows efficacy in a murine model of Netherton syndrome
A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
research Topical delivery of nanoemulsions for skin cancer treatment
Nanoemulsions can effectively treat skin cancer with fewer side effects.
research Perspective Chapter: Appraisal of Paclitaxel (Taxol) Pros and Cons in the Management of Cancer – Prospects in Drug Repurposing
Paclitaxel is an effective cancer drug with side effects and potential new uses beyond cancer.
research Nonmelanoma skin cancer treated with electronic brachytherapy: Results at 1 year
HDR electronic brachytherapy effectively treats nonmelanoma skin cancer with good cosmetic results and minimal side effects.
research VP-16-213 (etoposide): The mandrake root from Issyk-Kul
Etoposide is effective in treating several cancers, especially small cell lung cancer, with acceptable side effects.
research Abstracts from the ASA 40thAnnual Meeting
HNG may help prevent the negative effects of chemotherapy on sperm production and white blood cell counts.
research USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research A distinct cutaneous reaction to sorafenib and a multikinase inhibitor
Sorafenib can cause a unique skin reaction.
research A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results
Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
research RETRACTED: The investigation and comparison of the efficacy and safety of stromal vascular fraction (SVF), platelet rich plasma (PRP), and 1064‐nm Q‐switched Nd:YAG laser in reducing nanofat treated infraorbital dark circles and wrinkles: A controlled blinded randomized clinical trial
Combining treatments significantly reduces dark circles and wrinkles better than nanofat alone.
research Acne keloidalis nuchae in renal transplant patients receiving tacrolimus and sirolimus
Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.
research Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment.
Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
research Reversal of Alopecia Universalis by Tofacitinib: A Case Report
Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
research Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
Tofacitinib helped a woman with total-body hair loss grow her hair back.
research Review of Drug Repositioning in Cancer Therapeutics
Repurposing existing drugs can improve cancer treatment but faces challenges.
research Formulation optimization, in vitro and in vivo evaluation of niosomal nanocarriers for enhanced topical delivery of cetirizine
Niosomes can effectively deliver cetirizine topically for treating alopecia.
research P0881 Effectiveness and Safety of Tofacitinib in Biologic-Naïve Elderly Patients with Ulcerative Colitis
Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
research A clinical case of familial alopecia areata in combination with immune pathology
Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.
research Scanning electron microscopy of ibrutinib-induced hair shaft changes
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Paclitaxel/Platinum combination regimen and alopecia
Most patients experienced significant but reversible hair loss during treatment.
research Genome Wide Differential Expression Profiles in Nevus Sebaceous Uncovered Low Expression of CDKN2AIP and Construction of a ceRNA Network
CDKN2AIP gene is less active in nevus sebaceous, affecting related RNA networks.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.